Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
National Institute on Aging
Headquarters: Bethesda, MD, United States of America
Website: http://www.nia.nih.gov
Year Founded: 1974
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 29, 2024
Finance
Public equity report: Avalo gets makeover with PIPE, acquisition
Plus: A PIPE for CervoMed ahead of dementia readout; and Stoke, Praxis follow clinical readouts with opportunistic follow-ons
BioCentury | Jul 22, 2023
Discovery & Translation
SIGLEC9 inhibition for glioblastoma; plus Long COVID genetic risks and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 8, 2023
Regulation
Leqembi – FDA’s chance for an Alzheimer’s do-over
Three reasons why FDA’s meeting to discuss lecanemab will be less contentious than its aducanumab meeting
BioCentury | Mar 31, 2023
Deals
March 30 Quick Takes: Scynexis deal gives GSK another anti-infective
Plus: AstraZeneca in-licenses CLDN18.2 asset from China’s KYM, updates from newly public biotechs Apollomics and GI Innovation and more
BioCentury | May 26, 2022
Product Development
National Academies tasks all parties with improving clinical trial diversity
The Academies’ 17-part plan involves industry, journals, FDA, CMS and more. The cost of not acting will reach hundreds of billions, it says.
BioCentury | Apr 15, 2022
Finance
Years after failed IPO attempts, Alzheon raises $50M round for Alzheimer’s study
With Phase III Alzheimer’s trial finally in progress, Alzheon’s new $50M series D arrives four years after first attempt to go public
BioCentury | Jul 1, 2021
Finance
Seizing the day, RA-backed Acumen tests market’s appetite for Alzheimer’s approach
Two and half decades after it was founded, Acumen goes public with revived amyloid therapy
BioCentury | Jun 11, 2021
Targets & Mechanisms
Not all amyloids are the same - who’s targeting what and how it’s going: Data Byte
A look at the specificities and progress of anti-amyloid therapies in the clinic
BioCentury | Mar 15, 2021
Product Development
Alzheimer’s data from Lilly and Biogen converge on small effect for amyloid targeting
Both corroborate the amyloid hypothesis while simultaneously suggesting it’s not the path to a large effect size
BioCentury | Nov 7, 2020
Regulation
Aducanumab panel criticizes FDA as it rebukes Alzheimer’s candidate
Clear path to approval for Biogen’s aducanumab scuttled by FDA panel
Items per page:
1 - 10 of 71